European Medicines Agency Validates Marketing Authorization Application for Pfizer and Valneva's Lyme Disease Vaccine Candidate

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate developed by Pfizer and Valneva. This marks a significant step towards potentially bringing the first vaccine for Lyme disease to Europe, following strong efficacy demonstrated in the Phase 3 VALOR trial.